BioAge Labs, Inc. (BIOA)
NASDAQ:BIOA
Want to see BIOA full AI Analyst Report?
BIOA Stock Chart & Stats
$18.49
-$0.31(-5.78%)
At close: 4:00 PM EST
$18.49
-$0.31(-5.78%)
Day’s Range― - ―
52-Week Range$4.07 - $24.00
Previous CloseN/A
Volume146.35K
Average Volume (3M)385.89K
Market Cap
$731.25M
Enterprise Value$413.22M
Total Cash (Recent Filing)$383.19M
Total Debt (Recent Filing)$4.03M
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Aug 12, 2026EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.40
Shares Outstanding44,452,736
10 Day Avg. Volume291,242
30 Day Avg. Volume385,891
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)1.75
Price to Sales (P/S)52.85
P/FCF Ratio-5.77
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue40.06
Enterprise Value/Gross Profit40.30
Enterprise Value/Ebitda-4.63
Forecast
1Y Price Target
$42.20Price Target Upside128.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.56
Revenue Forecast (FY)$6.14M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet & Low LeverageBioAge’s unusually large capital base and low debt provide a durable financial cushion for an R&D‑intensive biotech. Substantial cash and securities reduce near‑term refinancing pressure, enabling multi‑year clinical programs and strategic optionality without immediate revenue dependence.
Advancing Lead Program (BGE‑102) Through ClinicPositive Phase 1 biomarker results and planned Phase 2a expansion materially de‑risk the program’s development path. Progress toward cardiovascular and ophthalmology indications increases potential addressable markets and supports a multi‑indication clinical strategy over the next 2–3 years.
Strategic Partnerships And Discovery EngineCollaborations with large pharma and ongoing large‑scale molecular profiling bolster BioAge’s target discovery and validation capabilities. These partnerships provide scientific validation, potential non‑dilutive funding or milestones, and strengthen long‑term pipeline generation prospects.
Bears Say
High Cash BurnSustained negative operating and free cash flow at near‑nine‑figure annualized levels is structurally significant for an early‑stage biopharma. Persistent burn requires disciplined capital allocation and ongoing financing capacity, limiting runway predictability if clinical timelines slip.
Large Operating/net Losses Vs Modest RevenueRevenue remains immaterial relative to operating expense scale, producing deep recurring losses. This structural mismatch means near‑term profitability is unlikely absent major product or partnership revenue, constraining self‑funding and increasing reliance on capital markets.
Ongoing Dependence On Financing Despite RunwayWhile current cash supports several years of operations, the business model’s negative cash flow makes the company structurally reliant on periodic capital raises or partner funding to progress multiple clinical programs concurrently, creating execution and dilution risk if markets tighten.
BioAge Labs, Inc. News
BIOA FAQ
What was BioAge Labs, Inc.’s price range in the past 12 months?
BioAge Labs, Inc. lowest stock price was $4.07 and its highest was $24.00 in the past 12 months.
What is BioAge Labs, Inc.’s market cap?
BioAge Labs, Inc.’s market cap is $731.25M.
When is BioAge Labs, Inc.’s upcoming earnings report date?
BioAge Labs, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 60 days.
How were BioAge Labs, Inc.’s earnings last quarter?
BioAge Labs, Inc. released its earnings results on May 08, 2026. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.64 by $0.12.
Is BioAge Labs, Inc. overvalued?
According to Wall Street analysts BioAge Labs, Inc.’s price is currently Undervalued.
Does BioAge Labs, Inc. pay dividends?
BioAge Labs, Inc. does not currently pay dividends.
What is BioAge Labs, Inc.’s EPS estimate?
BioAge Labs, Inc.’s EPS estimate is -0.61.
How many shares outstanding does BioAge Labs, Inc. have?
BioAge Labs, Inc. has 44,452,736 shares outstanding.
What happened to BioAge Labs, Inc.’s price movement after its last earnings report?
BioAge Labs, Inc. reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.64. Following the earnings report the stock price went up 0.954%.
Which hedge fund is a major shareholder of BioAge Labs, Inc.?
Currently, no hedge funds are holding shares in BIOA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioAge Labs, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.20 (128.23% Upside)
$42.20 (128.23% Upside)
Blogger Sentiment
Bearish
BIOA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 8.2%
Last 30 Days ▲ 8.2%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
270.49%
12-Months-Change
Fundamentals
Return on Equity
-29.40%
Trailing 12-Months
Asset Growth
15.65%
Trailing 12-Months
Company Description
BioAge Labs, Inc.
BioAge Labs, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for metabolic illnesses. The company employs a distinctive technology platform alongside specialized human datasets to pinpoint potential drug targets by unraveling the molecular mechanisms underlying the aging process. Their current pipeline features azelaprag, an oral small molecule, which is undergoing Phase 1 clinical trials for obesity. Additionally, BioAge has commenced a Phase 2 clinical trial for azelaprag, investigating its efficacy in combination with tirzepatide for managing obesity specifically in older adults. Another asset under development is BGE-100, an oral, brain-penetrant small molecule designed to act as an NLRP3 antagonist, aiming to address conditions characterized by neuroinflammation. Established in 2015, BioAge Labs, Inc. operates from its headquarters in Richmond, California.
BIOA Stock 12 Month Forecast
Average Price Target
$42.20
▲(128.23% Upside)
Technical Analysis
Ironwood Pharma
―
Lifecore Biomedical
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
Incannex Healthcare Limited Sponsored ADR
―
Ownership Overview
9.56% Insiders
5.93% Mutual Funds
44.02% Other Institutional Investors
31.17% Public Companies and
Individual Investors